Latest Nicholas J. Vogelzang Stories
HORSHAM, Pa., March 30, 2015 /PRNewswire/ -- The U.S.
The Oncology Institute of Hope and Innovation announces the opening of the following clinical trial that may benefit some prostate cancer patients. Downey, CA
Data from Multiple Studies Include Potential Ability for Technology to Further Subtype Patients, Guide Treatment Decisions SAN DIEGO, Feb.
Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2015 ASCO Genitourinary Symposium SAN DIEGO, Feb.
Results, Published in Clinical Genitourinary Cancer, Offer Key Insights and Potential New Treatment Strategies for Patient Population with Limited Drug Options IRVING, Texas, Oct.
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept.
Researchers say pemetrexed (Alimta), the top chemotherapy drug for mesothelioma, may carry a risk of acute kidney injury, even in patients whose baseline kidney function falls within recommended
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus
- Growing in low tufty patches.